

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase II CodeBreaK 100 trial investigating sotorasib for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS p.G12C mutation revealed a median duration of response with sotorasib of approximately how many months?

 - a. 3
 - b. 6.5
 - c. 11
 - d. 15
2. Which of the following is a target for patritumab deruxtecan?

 - a. EGFR
 - b. HER2
 - c. HER3
 - d. ROS1
3. Which of the following outcomes was reported from the Phase II VISION study investigating the association between molecular and clinical responses in patients with advanced NSCLC with a MET exon 14 skipping alteration or MET amplification who received tepotinib?

 - a. Molecular progression was associated with durable response/long progression-free survival
 - b. Molecular progression was associated with lack of response/short progression-free survival
 - c. Molecular response was not associated with clinical response
4. Amivantamab is approved for which of the following EGFR mutations in locally advanced or metastatic non-small cell lung cancer progressing on or after platinum-based chemotherapy?

 - a. Exon 19 deletions
 - b. Exon 20 insertions
 - c. L858R
 - d. All known EGFR mutations